Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer

Breast Cancer Clinical Trial

Official title: Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer Who Have Residual Disease After Neoadjuvant Systemic Therapy

Status Recruiting

Clinical Trial Summary

Breast cancer patients who undergo neoadjuvant systemic therapy and have residual breast cancer identified at the time of surgery exhibit a high (>50%) risk of future life-threatening recurrences and death.

Clinical Trial Description

This study is being done to collect blood and leftover surgical tissue from patients with breast cancer remaining after chemotherapy or endocrine therapy is completed. We will use the blood and tissue for future studies. These studies will try to find ways to treat future breast cancer patients.

Because there is cancer left in your body after breast cancer treatment is finished, we think the cancer may be different than other cancers. Tissue from surgery will be used to try to grow that kind of cancer in the lab so we can find out more about it and how to treat it.

Blood samples will be used to look at measurements of biomarkers to see how this cancer is different and seek new ways to identify and treat it. ;

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms
• Residual

• NCT number: NCT04703244
• Study type: Observational
• Source: Mayo Clinic
• Contact: Clinical Trials Referral Office
• Phone: 855-776-0015
• Email: mayocliniccancerstudies@mayo.edu
• Status: Recruiting
• Start date: January 13, 2021
• Completion date: January 15, 2042